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Background: Occurrence of bleeding complications represents a predictor of poorer outcome in patients undergoing percutaneous coronary 
intervention (PCI); an enhanced degree of response to antiplatelet agents may translate into a higher risk of bleeding. Aim of this study was to 
evaluate whether low platelet reactivity by point-of-care measurement of platelet inhibition after clopidogrel administration correlates with bleeding 
complications after PCI. 
Methods: A total of 310 patients receiving clopidogel pre-PCI were prospectively enrolled. Platelet reactivity was measured by the VerifyNowTM 
P2Y12 assay. Primary endpoint was 30-day incidence of major bleeding/entry site complications according to quartile distribution of P2Y12 reaction 
units (PRU).
Results: Primary end-point occurred more frequently in patients with pre-procedural PRU levels in the 1st quartile vs those in the highest quartile 
(10.1% vs 1.3%; P=0.043), and it was mainly due to entry-site hemorrhages. Mean PRU absolute levels were lower in patients with major bleeding 
(171±49 vs 227±68 in patients without; P=0.002). On multivariable analysis, pre-PCI PRU levels in the 1st quartile were associated with >4.5-fold 
increased risk of major bleeding (OR 4.5, 95% CI 1.9-25.9; P=0.01). By receiver-operating characteristic (ROC) curve analysis, the optimal cut-off for 
the primary end-point was a pre-PCI PRU value ≤189 (area under the curve 0.76, 95% CI 0.66-0.87; P=0.001).
Conclusions: Our study suggests that an enhanced response to clopidogrel may be associated with a higher risk of early major bleeding/entry site 
complications in patients undergoing PCI. Use of a rapid point-of-care assay for monitoring platelet reactivity after clopidogrel administration may 
help identify patients in whom individualized strategies are indicated in order to avoid bleeding complications after coronary intervention. 
